Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference. Cantor Global Healthcare Conference Fireside Chat on Wednesday, September 9, 2026 at 8:00am ET The presentation will premiere at the time listed above
Yahoo2 days agoALGS
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates
Aligos Therapeutics (NASDAQ:ALGS) shares rose 7. 6% to $6.
Yahoo2 days agoALGS
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS) shares
Benzinga2 days agoALGS
Aligos Therapeutics Initiates Dosing In Phase 1 Study Of ALG-170675, Investigational Next-Gen Antisense Oligonucleotide Being Evaluated For Functional Cure In Treatment Of Chronic HBV Infection
ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026SOUTH
Benzinga23 days agoALGS
Keep an eye on the top gainers and losers in Monday's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
ChartMill25 days agoALGS
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release, H1 earnings
Benzinga25 days agoALGS
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2026. “Our team has continued to execute on our key strategic priorities to advance our pipeline this year,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, Pres
Yahoo29 days agoALGS
Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(1.07) by 86.92 percent. This is a 90.85 percent increase over losses of $(1.53) per share
Benzinga29 days agoALGS